Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988331368> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2988331368 abstract "Atorvastatin (ATV) is an anticholesteremic agent, HMG-CoA reductase inhibitor approved for clinical use as a lipid lowering agent. ATV, the world’s best-selling drug is frequently associated with implications of the low solubility and poor dissolution which affects its rate of absorption, resulting in a low oral bioavailability and have some complications. Nanoemulsion (NE) is an advanced mode of drug delivery system that has been developed for improving the delivery of therapeutic agents. The aim of this study was to develop and assess the ability of the NE in enhancing ATV bioavailability and minimizing its side effects in hyperlipidemic rats. Thirty five rats were divided into seven groups at which group has five rats. Hyperlipidemia was induced by feeding the animals high fat diet for 3 months and half. The antihyperlipidemic activity of 10 and 20 mg/kg of ATV loaded in two different delivery system, either loaded in nanoemulsion (10% and 20% ATV-LNE) or in water (10% and 20% ATV-sol) were investigated. The effectiveness of ATV formulations were assessed by measuring the change in body weight, serum and plasma biochemical parameters (lipid profile, glucose, insulin, liver function, kidney function, oxidative stress marker ( and studying the histopathological changes of the liver and kidney tissues. The physical characteristics of NE were determined by the Zetasizer (the z-average diameter and zeta potential). The 20% ATV-LNE has the smallest nanoparticles (38.12 ± 6.71nm) whereas it has the largest zeta negative potential of -26.8 ± 4.16mV. The serum biochemical results and the histopathological examination revealed that treatment with 20% ATV-LNE improved the lipid profile by significantly increasing HDL and decreasing cholesterol and low density lipoprotein. Also, serum glucose level was reduced in both 10 and 20% ATV-LNE compared to solution formulations. In addition, Alkaline Phosphatase (ALP) levels in all NE treated groups were lower than solution treated groups. In conclusion, the NE formulas have the potential to improve the bioavailability and efficacy of ATV and reduce its side effects." @default.
- W2988331368 created "2019-11-22" @default.
- W2988331368 creator A5073309904 @default.
- W2988331368 date "2017-01-01" @default.
- W2988331368 modified "2023-09-27" @default.
- W2988331368 title "Hypolipidemic effect of Atorvastatin- Loaded- Nanoemulsion in Rats" @default.
- W2988331368 hasPublicationYear "2017" @default.
- W2988331368 type Work @default.
- W2988331368 sameAs 2988331368 @default.
- W2988331368 citedByCount "0" @default.
- W2988331368 crossrefType "journal-article" @default.
- W2988331368 hasAuthorship W2988331368A5073309904 @default.
- W2988331368 hasConcept C125287762 @default.
- W2988331368 hasConcept C134018914 @default.
- W2988331368 hasConcept C155672457 @default.
- W2988331368 hasConcept C159985019 @default.
- W2988331368 hasConcept C171250308 @default.
- W2988331368 hasConcept C178790620 @default.
- W2988331368 hasConcept C181389837 @default.
- W2988331368 hasConcept C185592680 @default.
- W2988331368 hasConcept C192562407 @default.
- W2988331368 hasConcept C2777482532 @default.
- W2988331368 hasConcept C2779091943 @default.
- W2988331368 hasConcept C2779820397 @default.
- W2988331368 hasConcept C2780035454 @default.
- W2988331368 hasConcept C555293320 @default.
- W2988331368 hasConcept C71924100 @default.
- W2988331368 hasConcept C86181022 @default.
- W2988331368 hasConcept C98274493 @default.
- W2988331368 hasConceptScore W2988331368C125287762 @default.
- W2988331368 hasConceptScore W2988331368C134018914 @default.
- W2988331368 hasConceptScore W2988331368C155672457 @default.
- W2988331368 hasConceptScore W2988331368C159985019 @default.
- W2988331368 hasConceptScore W2988331368C171250308 @default.
- W2988331368 hasConceptScore W2988331368C178790620 @default.
- W2988331368 hasConceptScore W2988331368C181389837 @default.
- W2988331368 hasConceptScore W2988331368C185592680 @default.
- W2988331368 hasConceptScore W2988331368C192562407 @default.
- W2988331368 hasConceptScore W2988331368C2777482532 @default.
- W2988331368 hasConceptScore W2988331368C2779091943 @default.
- W2988331368 hasConceptScore W2988331368C2779820397 @default.
- W2988331368 hasConceptScore W2988331368C2780035454 @default.
- W2988331368 hasConceptScore W2988331368C555293320 @default.
- W2988331368 hasConceptScore W2988331368C71924100 @default.
- W2988331368 hasConceptScore W2988331368C86181022 @default.
- W2988331368 hasConceptScore W2988331368C98274493 @default.
- W2988331368 hasLocation W29883313681 @default.
- W2988331368 hasOpenAccess W2988331368 @default.
- W2988331368 hasPrimaryLocation W29883313681 @default.
- W2988331368 hasRelatedWork W1271554013 @default.
- W2988331368 hasRelatedWork W1968037630 @default.
- W2988331368 hasRelatedWork W1973423601 @default.
- W2988331368 hasRelatedWork W2041885280 @default.
- W2988331368 hasRelatedWork W2048948729 @default.
- W2988331368 hasRelatedWork W2068493308 @default.
- W2988331368 hasRelatedWork W2073433931 @default.
- W2988331368 hasRelatedWork W2095607717 @default.
- W2988331368 hasRelatedWork W2113452396 @default.
- W2988331368 hasRelatedWork W2215836808 @default.
- W2988331368 hasRelatedWork W2310955784 @default.
- W2988331368 hasRelatedWork W2350972557 @default.
- W2988331368 hasRelatedWork W2547226664 @default.
- W2988331368 hasRelatedWork W2603978658 @default.
- W2988331368 hasRelatedWork W2767288 @default.
- W2988331368 hasRelatedWork W2893953282 @default.
- W2988331368 hasRelatedWork W2898622440 @default.
- W2988331368 hasRelatedWork W2936909474 @default.
- W2988331368 hasRelatedWork W3207494133 @default.
- W2988331368 hasRelatedWork W2737451895 @default.
- W2988331368 isParatext "false" @default.
- W2988331368 isRetracted "false" @default.
- W2988331368 magId "2988331368" @default.
- W2988331368 workType "article" @default.